Interview with Pawel Ciapala, Managing Director, Ipsen Poland
When we look at the full year 2010 unaudited IFRS consolidated sales, we see that Ipsen performed very well in 2010 in Central and Eastern Europe. How has Poland alone…
Address: 00-867 Warszawa
al. Jana Pawła II 29
Tel: 22 653 68 00
Web: http://www.ipsen.pl/
Ipsen is a global biopharmaceutical group, with sales exceeding 1 billion euros in 2009. The Group has total worldwide staff of more than 4,400 employees, of which nearly 900 contribute to the discovery and development of innovative drugs for patient care.
Ipsen’s research & development (R&D) centers and its peptide & protein engineering platform give the Group a strong competitive edge. In 2009, R&D expenditure totaled close to €200 million, representing nearly 20% of Group sales.
Ipsen’s shares are traded on segment A of Euronext Paris (stock code: IPN, ISIN code: FR0010259150) and eligible to the “Service de Règlement Différé” (“SRD”). The Group is part of the SBF 120 index. Ipsen has implemented a Sponsored Level I American Depositary Receipt (ADR) program, which trade on the over-the-counter market in the United States under the symbol IPSEY.
Facts and figures in Poland:
Employment 30
Annual Turnover 80,000,000 zł.
Founded 1996
Ipsen’s development strategy is based on fast growing specialty care drugs in oncology, endocrinology, neurology and hematology, and on primary care drugs. This strategy is supported by an active policy of partnerships.
When we look at the full year 2010 unaudited IFRS consolidated sales, we see that Ipsen performed very well in 2010 in Central and Eastern Europe. How has Poland alone…
Iwona Skrzekowska-Baran, owner and CEO of Pharm&Med, a young, exciting Polish consultancy that is helping clients to transform evidence, policy insights, and market intelligence into effective market access strategies. She…
Leonardo Maffioli, senior marketing and commercial manager of the fertility and endocrinology division of IBSA, discusses the story of IBSA Poland and the potential of the Polish market for the…
Jacek Glinka, president of Mylan Europe, and Tomasz Buczek, country manager of Mylan Poland, discuss the intricate dynamics of the European and Polish pharmaceutical ecosystem and the steps required to…
Witold Włodarczyk, director general of Polmed (Polish chamber for medical devices), discusses the Polish medical device landscape and the policy surrounding the sector, especially the proposed 2016 reimbursement act. Furthermore,…
Krzysztof Łokaj, general manager of Chiesi Poland, discusses the positioning of the company as they become the absolute leaders in the respiratory field, driven by Fostex® and soon Trimbow®. Furthermore,…
Dariusz Głogowski, country manager of Alvogen Poland, discusses his successful strategy to introduce biosimilars onto the Polish market and the nation’s moves to reward this new wave of generics. Furthermore,…
Agnieszka Grzybowska-Zalewska, general manager of Sanofi Genzyme Poland, reflects on the company’s stable growth over the last few years and the market access challenges they have encountered along the way.…
Dr. Wolfgang Wagner, regional director of Wörwag EU and CEE, highlights the ongoing process of the company to integrate itself within each respective healthcare community so patients can receive better…
Paweł Przewięźlikowski, CEO of Selvita, the largest biotech company between Germany and India, discusses the first-in-class and pioneer Polish molecule, SEL24, and the future game changing molecule, SEL120 – the…
Mieczysław Wośko, president and founder of Polfarmex, a leading Polish company, discusses the key factors behind the enterprise’s successful growth and the movement towards R&D to create their own treatments.…
Michał Mieszkowski, general manager of Angelini Poland, discusses the strategic significance of Poland for the company, as the third largest affiliate within the global company, the company’s impressive product portfolio…
Stefan Buguslawski, president of PEX Pharmasequence, a leading Polish healthcare consultancy and market research company, highlights the current obstacles facing the Polish healthcare market and the dynamics of the domestic…
See our Cookie Privacy Policy Here